Vital Therapies, Inc. (NASDAQ:VTL) Director Muneer A. Satter acquired 10,000 shares of Vital Therapies stock in a transaction that occurred on Tuesday, June 13th. The shares were purchased at an average cost of $3.03 per share, with a total value of $30,300.00. The purchase was disclosed in a filing with the SEC, which is available at this link.
Vital Therapies, Inc. (NASDAQ VTL) traded down 3.33% during trading on Friday, reaching $2.90. 184,709 shares of the company’s stock were exchanged. The company’s market cap is $122.40 million. The stock’s 50-day moving average is $3.21 and its 200-day moving average is $4.17. Vital Therapies, Inc. has a 12-month low of $2.25 and a 12-month high of $8.14.
Vital Therapies (NASDAQ:VTL) last released its earnings results on Tuesday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.37) by $0.02. During the same period last year, the company posted ($0.31) earnings per share. Analysts predict that Vital Therapies, Inc. will post ($1.67) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.wkrb13.com/markets/2228797/muneer-a-satter-buys-10000-shares-of-vital-therapies-inc-vtl-stock.html.
Several hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its position in shares of Vital Therapies by 1.8% in the first quarter. Goldman Sachs Group Inc. now owns 64,545 shares of the company’s stock worth $258,000 after buying an additional 1,157 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Vital Therapies by 11.5% in the first quarter. Bank of New York Mellon Corp now owns 88,104 shares of the company’s stock worth $352,000 after buying an additional 9,120 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Vital Therapies by 5.8% in the first quarter. Geode Capital Management LLC now owns 172,210 shares of the company’s stock worth $688,000 after buying an additional 9,448 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Vital Therapies by 1.6% in the first quarter. Vanguard Group Inc. now owns 845,858 shares of the company’s stock worth $3,383,000 after buying an additional 13,654 shares during the last quarter. Finally, State Street Corp raised its stake in shares of Vital Therapies by 6.0% in the fourth quarter. State Street Corp now owns 328,091 shares of the company’s stock worth $1,427,000 after buying an additional 18,645 shares during the last quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.
VTL has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Vital Therapies from a “sell” rating to a “hold” rating in a research note on Wednesday, May 10th. BTIG Research reaffirmed a “hold” rating on shares of Vital Therapies in a research note on Friday, March 10th. Raymond James Financial, Inc. initiated coverage on shares of Vital Therapies in a research note on Thursday, May 18th. They set an “outperform” rating and a $6.00 price objective for the company. Finally, ValuEngine cut shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Vital Therapies currently has an average rating of “Hold” and an average price target of $8.00.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2228797/muneer-a-satter-buys-10000-shares-of-vital-therapies-inc-vtl-stock.html
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.